Last reviewed · How we verify
Intravenous Formulation of PD-0332991
Intravenous Formulation of PD-0332991 is a Small molecule drug developed by Pfizer. It is currently in Phase 1 development.
At a glance
| Generic name | Intravenous Formulation of PD-0332991 |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer (PHASE1, PHASE2)
- Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia (PHASE1, PHASE2)
- A Study Comparing the Plasma Drug Exposure of an Oral Dose of Palbociclib (PD-0332991) to an Intravenous Dose of Palbociclib (PD-0332991) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous Formulation of PD-0332991 CI brief — competitive landscape report
- Intravenous Formulation of PD-0332991 updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Intravenous Formulation of PD-0332991
What is Intravenous Formulation of PD-0332991?
Intravenous Formulation of PD-0332991 is a Small molecule drug developed by Pfizer.
Who makes Intravenous Formulation of PD-0332991?
Intravenous Formulation of PD-0332991 is developed by Pfizer (see full Pfizer pipeline at /company/pfizer).
What development phase is Intravenous Formulation of PD-0332991 in?
Intravenous Formulation of PD-0332991 is in Phase 1.